A study has also shown that non-response to the anti-PD-L1 antibody atezolizumab in a cohort of metastatic urothelial cancer patients was correlated with the exclusion of CD8+ T cells from the tumour and their accumulation in the tumour stroma [101]. This evidence concerns the gene CD8A and neoplasm.